Tumors with ALK rearrangements can harbor more mutations
(International Association for the Study of Lung Cancer) The identification of potentially targetable kinase mutations has been an exciting advancement in lung cancer treatment. Although the mutations driving many lung carcinomas remain unknown, approximately 50 percent of lung adenocarcinoma cases harbor KRAS mutation, EGFR mutation, or ALK translocation, and an additional 5 percent or so have been shown to have mutations involving BRAF, PIK3CA, HER2, MET, MEK1, NRAS, and AKT. In the vast majority, these driver mutations are mutually exclusive. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - April 22, 2013 Category: Global & Universal Source Type: news
Safety and Efficacy of Talactoferrin in Patients With SepsisSafety and Efficacy of Talactoferrin in Patients With Sepsis
How does enteral administration of talactoferrin impact translocation of bacteria from the gut into the systemic circulation? Critical Care Medicine (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - April 3, 2013 Category: Consumer Health News Tags: Critical Care Journal Article Source Type: news
IMI launches first antimicrobial resistance projects
Source: PharmaTimes
Area: News
The European Union's Innovative Medicines Initiative (IMI) has launched the first two projects under its research programme for antimicrobial resistance. The projects, launched under the New Drugs for Bad Bugs (ND4BB) programme are COMBACTE (Combating Bacterial Resistance in Europe) and TRANSLOCATION (Molecular basis of the bacterial cell wall permeability):
. The COMBACTE team plans to develop innovative trial designs that will facilitate the registration of novel antibacterial agents. It will also design and validate tests to support patient diagnoses, identify the most app...
Source: NeLM - News - February 12, 2013 Category: Drugs & Pharmacology Source Type: news
Identification of Legionella Effectors Using Bioinformatic Approaches
Legionella pneumophila the causative agent of Legionnaires’ disease, actively manipulates host cell processes to establish a replication niche inside host cells. The establishment of its replication niche requires a functional Icm/Dot type IV secretion system which translocates about 300 effector proteins into host cells during infection. Many of these effectors were first identified as effector candidates by several bioinformatic approaches, and these predicted effectors were later examined experimentally for translocation and a large number of which were validated as effector proteins. Here, I summarized the bioinf...
Source: Springer protocols feed by Infectious Diseases - February 1, 2013 Category: Infectious Diseases Source Type: news
MRD Detection in B-Cell Non-Hodgkin Lymphomas Using Ig Gene Rearrangements and Chromosomal Translocations as Targets for Real-Time Quantitative PCR
Minimal residual disease (MRD) diagnostics is of high clinical relevance in patients with indolent B-cell Non-Hodgkin lymphomas (B-NHL) and serves as a surrogate parameter to evaluate treatment effectiveness and long-term prognosis. MRD diagnostics performed by real-time quantitative PCR (RQ-PCR) is the gold-standard and currently the most sensitive and the most broadly applied method in follicular lymphoma (FL) and mantle cell lymphoma (MCL). RQ-PCR analysis of the junctional regions of the rearranged immunoglobulin heavy-chain gene (IgH) serves as the most broadly applicable MRD target in B-NHL (∼80%). Chromosomal tr...
Source: Springer protocols feed by Cancer Research - January 11, 2013 Category: Cancer & Oncology Source Type: news
Summaries: International Kidney Cancer Symposium
Conclusion: there is no increased risk of doing the lymph node dissection early on.
Dr. Eggener-CON
Basics
Lymph node dissections rarely done, even for large tumors, because there is no proven therapeutic or staging benefit for low risk patients. A Mayo study revealed no data showing therapeutic benefit in high risk patients. For clinically node negative high risk patients, there is staging value but no proven therapeutic benefit.
Rate of positive nodes is associated with stage and grade; the higher the stage and grade, the more likely there will be positive nod...
Source: Kidney Cancer Association - November 29, 2011 Category: Urology & Nephrology Source Type: news
Summaries: International Kidney Cancer Symposium
Conclusion: there is no increased risk of doing the lymph node dissection early on. Dr. Eggener-CON
Basics
Lymph node dissections rarely done, even for large tumors, because there is no proven therapeutic or staging benefit for low risk patients. A Mayo study revealed no data showing therapeutic benefit in high risk patients. For clinically node negative high risk patients, there is staging value but no proven therapeutic benefit.
Rate of positive nodes is associated with stage and grade; the higher the stage and grade, the more likely there will be positive nodes. A tumor> 10 cm w...
Source: Kidney Cancer Association - November 29, 2011 Category: Urology & Nephrology Source Type: news
NCCN Updates Dermatofibrosarcoma Protuberans Guidelines
JENKINTOWN, Pa., September 11, 2007 — The National Comprehensive Cancer Network (NCCN) announces important updates to the NCCN Dermatofibrosarcoma Protuberans (DFSP) Guidelines. DFSP is a rare, low-grade sarcoma characterized by a t(17;22) chromosomal translocation resulting in the over-expression of platelet-derived growth factor receptor '(PDGFRB). This abnormal proliferation of cells can quickly grow into a malignant tumor.
In a phase II open-label trial—Study B2225, the largest study invol... (Source: National Comprehensive Cancer Network)
Source: National Comprehensive Cancer Network - September 11, 2007 Category: Cancer & Oncology Source Type: news
